The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday. Patrizia Cavazzoni was formerly director ...

Kennedy Jr., a longtime vaccine critic who has campaigned for the president on promises to shake up the FDA, as the new secretary of Health and Human Services Department. At Pfizer, she will be an ...

Pfizer’s prostate cancer therapy Talzenna, when combined with Xtandi, can extend overall survival (OS) by nearly nine months over the standard of care (SoC), according to a Phase III trial.

Both Talzenna and Xtandi are FDA-approved. Xtandi is co-marketed by Pfizer (PFE) and Astellas (OTCPK:ALPMF).

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with ...

The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder transthyretin cardiac amyloidosis in a potential setback to Pfizer (NYSE ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. Now, with new data indicating the drug could prolong patients’ lives, the company ...

(RTTNews) - Pfizer Inc. (PFE ... compared to Xtandi alone. Talzenna in combination with Xtandi is already approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult ...

Pfizer said it plans to share the results with global health authorities to potentially update Talzenna's label. The FDA had also approved AstraZeneca's Lynparza in combination with hormone ...

“The Board should not allow Moderna to opportunistically embrace prior art before the FDA but now distance itself from the same prior art here.” – Pfizer’s brief to PTAB In a recent brief ...

The FDA has greenlighted Pfizer’s Talzenna, in combination with the company’s Astellas-partnered Xtandi, to treat metastatic castration-resistant prostate cancer (mCRPC) that has homologous ...